Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479621 | 0.97 | ATM (0.39) | ATMMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL8292992 | 0.91 | MEN1 (0.39) | ATMMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL5483406 | 0.87 | ALOX5AP (0.39) | ATMMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL5484745 | 0.84 | ATM (0.39) | ATMF2ALOX5APFEN1CHEK2 | |
| SCHEMBL5479364 | 0.83 | CHEK2 (0.39) | ATMMEN1KMT2AF2ALOX5AP | |
| SCHEMBL5481717 | 0.82 | ATM (0.39) | ATMMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL7023932 | 0.81 | PRMT5 (0.42) | MEN1KMT2AF2ALDH1A1ALOX5AP | |
| SCHEMBL7022729 | 0.81 | PRMT5 (0.42) | MEN1KMT2AF2ALDH1A1ALOX5AP | |
| SCHEMBL7023114 | 0.81 | PRMT5 (0.42) | MEN1KMT2AF2ALDH1A1ALOX5AP | |
| SCHEMBL5483612 | 0.77 | ATM (0.39) | ATMALDH1A1ALOX5APFEN1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | ATM 1490/4885MEN1 3103/4885KMT2A 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.